Evidence map›Paper›PMID 29114018›Full record

ArticleRNA (New York, N.Y.)2018

Accurate detection of chemical modifications in RNA by mutational profiling (MaP) with ShapeMapper 2.

Steven Busan, Kevin M Weeks

Open access · bronzeAbstract read
In one paragraph

Article in RNA (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers.

0numbers the graph read from it
0cells of the map it votes in
189citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

189 citing papers in PubMed, 257 citations in OpenAlex.

  1. A B1 SINE element within the mouseScience advances · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Divergent RNA structures support accurate splicing of the SF3B1-sensitivebioRxiv : the preprint server for biology · 2026
    Article
  18. Article
  19. Article
  20. Review

129 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Steven BusanDepartment of Chemistry, University of North Carolina, Chapel Hill, North Carolina 27599-3290, USA.
Kevin M WeeksDepartment of Chemistry, University of North Carolina, Chapel Hill, North Carolina 27599-3290, USA weeks@unc.edu.ORCID 0000-0002-6748-9985
University of North Carolina at Chapel Hill · US

Funding

Structure of the HIV-1 GenomeR01AI068462 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WEEKS, KEVIN M · 2006 to 2020
$7.4M
NIAID NIH HHS R01 AI068462
6 · The paper itself

Abstract

Mutational profiling (MaP) enables detection of sites of chemical modification in RNA as sequence changes during reverse transcription (RT), subsequently read out by massively parallel sequencing. We introduce ShapeMapper 2, which integrates careful handling of all classes of adduct-induced sequence changes, sequence variant correction, basecall quality filters, and quality-control warnings to now identify RNA adduct sites as accurately as achieved by careful manual analysis of electrophoresis data, the prior highest-accuracy standard. MaP and ShapeMapper 2 provide a robust, experimentally concise, and accurate approach for reading out nucleic acid chemical probing experiments.

Indexed as

MutationBase PairingHigh-Throughput Nucleotide SequencingRNASequence Analysis, RNASoftwareRNA1M61M75NIAcorrelated chemical probingdimethyl sulfatemutational profilingNAINMIARINGRNA structure modelingSHAPEsingle molecule

Identifiers

PMID29114018
PMCPMC5769742
OpenAlexW2767747597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.